Khodzhaeva Vera, Makeeva Anna, Ulyanova Vera, Zelenikhin Pavel, Evtugyn Vladimir, Hardt Martin, Rozhina Elvira, Lvov Yuri, Fakhrullin Rawil, Ilinskaya Olga
Institute of Fundamental Medicine and Biology, Kazan Federal UniversityKazan, Russia.
Imaging Unit, Biomedical Research Center Seltersberg, Justus Liebig University GiessenGiessen, Germany.
Front Pharmacol. 2017 Sep 12;8:631. doi: 10.3389/fphar.2017.00631. eCollection 2017.
Many ribonucleases (RNases) are considered as promising tools for antitumor therapy because of their selective cytotoxicity toward cancer cells. Binase, the RNase from , triggers apoptotic response in cancer cells expressing oncogene which is mutated in a large percentage of prevalent and deadly malignancies including colorectal cancer. The specific antitumor effect of binase toward RAS-transformed cells is due to its direct binding of RAS protein and inhibition of downstream signaling. However, the delivery of proteins to the intestine is complicated by their degradation in the digestive tract and subsequent loss of therapeutic activity. Therefore, the search of new systems for effective delivery of therapeutic proteins is an actual task. This study is aimed to the investigation of antitumor effect of binase immobilized on natural halloysite nanotubes (HNTs). Here, we have developed the method of binase immobilization on HNTs and optimized the conditions for the enzyme loading and release (i); we have found the non-toxic concentration of pure HNTs which allows to distinguish HNTs- and binase-induced cytotoxic effects (ii); using dark-field and fluorescent microscopy we have proved the absorption of binase-loaded HNTs on the cell surface (iii) and demonstrated that binase-halloysite nanoformulations possessed twice enhanced cytotoxicity toward tumor colon cells as compared to the cytotoxicity of binase itself (iv). The enhanced antitumor activity of biocompatible binase-HNTs complex confirms the advisability of its future development for clinical practice.
许多核糖核酸酶(RNases)因其对癌细胞的选择性细胞毒性而被视为抗肿瘤治疗的有前景的工具。来自[具体来源未提及]的Binase核糖核酸酶,能在表达[具体癌基因未提及]癌基因的癌细胞中引发凋亡反应,该癌基因在包括结直肠癌在内的大量常见致命恶性肿瘤中发生突变。Binase对RAS转化细胞的特异性抗肿瘤作用归因于其与RAS蛋白的直接结合以及对下游信号传导的抑制。然而,蛋白质在肠道中的递送因它们在消化道中的降解以及随后治疗活性的丧失而变得复杂。因此,寻找有效递送治疗性蛋白质的新系统是一项实际任务。本研究旨在调查固定在天然埃洛石纳米管(HNTs)上的Binase的抗肿瘤作用。在此,我们开发了将Binase固定在HNTs上的方法,并优化了酶负载和释放的条件(i);我们发现了纯HNTs的无毒浓度,这使得能够区分HNTs和Binase诱导的细胞毒性作用(ii);使用暗场和荧光显微镜,我们证明了负载Binase的HNTs在细胞表面的吸收(iii),并证明与Binase本身的细胞毒性相比,Binase-埃洛石纳米制剂对肿瘤结肠细胞的细胞毒性增强了两倍(iv)。生物相容性Binase-HNTs复合物增强的抗肿瘤活性证实了其未来用于临床实践开发的可取性。